Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10358568 | 1.00 | PLK1 (0.33) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL10354160 | 0.94 | PLK1 (0.31) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL667482 | 0.86 | PLK1 (0.37) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL29684841 | 0.86 | PLK1 (0.37) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL29684619 | 0.84 | PLK1 (0.35) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL667491 | 0.84 | PLK1 (0.35) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL21218965 | 0.82 | PLK1 (0.32) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL5057465 | 0.81 | ABCB1 (0.48) | PLK1SMN1; SMN2ABCB1HPGD | |
| SCHEMBL667456 | 0.79 | PLK1 (0.39) | PLK1SMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL29684822 | 0.79 | PLK1 (0.39) | PLK1SMN1; SMN2NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-3000317-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1744619-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9163256-B2 | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system | INTREXON CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20120185954-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression | INTREXON CORPORATION (US) | 2012-07-19 | — | — | US | disclosed |
| US-8076454-B2 | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system | INTREXON CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| US-7935510-B2 | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system | INTREXON CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080216184-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | PALLI SUBBA REDDY | 2008-09-04 | — | — | US | disclosed |
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-1744619-A4 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1744619-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RheoGene, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | INTREXON CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005108617-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE,INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | PLK1 4120/4885SMN1; SMN2 4599/4885NPC1 781/4885 |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | PLK1 4120/4885SMN1; SMN2 4599/4885NPC1 781/4885 |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | NR2E3, NR1H4, NR5A2 | PLK1 4462/4885SMN1; SMN2 4560/4885NPC1 714/4885 |
| US-20080216184-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | PLK1 4120/4885SMN1; SMN2 4599/4885NPC1 781/4885 |
| US-20120185954-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression | NR2E3, NR5A2, NCOA3 | PLK1 4435/4885SMN1; SMN2 4611/4885NPC1 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.